Neumora Therapeutics, Inc.
NMRA
$1.20
-$0.05-4.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -212.75M | -222.39M | -236.93M | -236.30M | -252.09M |
| Total Depreciation and Amortization | 47.00K | 59.00K | 208.00K | 356.00K | 489.00K |
| Total Amortization of Deferred Charges | 2.02M | 1.93M | 1.51M | 303.00K | 303.00K |
| Total Other Non-Cash Items | 27.32M | 27.69M | 29.21M | 31.82M | 35.67M |
| Change in Net Operating Assets | 2.84M | -677.00K | -437.00K | -5.00M | 19.95M |
| Cash from Operations | -180.52M | -193.40M | -206.44M | -208.83M | -195.68M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | -16.00K | 0.00 |
| Sale of Property, Plant, and Equipment | 205.00K | 289.00K | 218.00K | 171.00K | 84.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 93.83M | 124.14M | 168.30M | 26.92M | 132.66M |
| Cash from Investing | 94.03M | 124.43M | 168.52M | 27.08M | 132.75M |
| Total Debt Issued | 38.76M | 57.16M | 57.16M | 18.26M | 18.40M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 40.48M | 30.80M | 19.93M | 15.41M | 17.16M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -445.00K | -- | -- | 225.00K | 0.00 |
| Cash from Financing | 78.80M | 87.96M | 77.09M | 33.89M | 35.56M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.69M | 19.00M | 39.17M | -147.86M | -27.37M |